Good news in the fight against the coronavirus. The pharmaceutical Modern has announced that the latest results obtained from its vaccine show that it is producing antibodies in adults. A piece of news that has been very well received on the trading floor, its shares have advanced by 0.33% after reaching more than 3.5%.
The study, published in the New England Journal of Medicine, offers a more complete picture of vaccine safety in older adults, a group at higher risk of serious complications from Covid-19. The findings are reassuring because immunity tends to weaken with age, Evan Anderson, one of the principal investigators of the study from Emory University in Atlanta, has explained in an interview to Reuters.
Moderna's vaccine is based on a new genetic technology that “offers advantages to stimulate protective responses in older populations”, Say the authors of the clinical trial.
Volunteers who have experienced side effects after receiving the doses are doing well – in fact, the researchers note that they are very similar to those produced by the flu vaccine. The most common being headache, fatigue, body aches, chills, and pain at the injection site, all of which were considered primarily mild and moderate.